# A Multicenter, Open Label Phase I Clinical Trial Evaluating the Safety and Pharmacokinetics of TQB2252 Injection in Subjects With Advanced Malignant Tumors

> **NCT06649656** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd.** · enrollment: 100 (estimated)

## Conditions studied

- Advanced Cancers

## Interventions

- **DRUG:** TQB2252 injection

## Key facts

- **NCT ID:** NCT06649656
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-11
- **Primary completion:** 2026-11
- **Final completion:** 2026-12
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2024-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06649656

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06649656, "A Multicenter, Open Label Phase I Clinical Trial Evaluating the Safety and Pharmacokinetics of TQB2252 Injection in Subjects With Advanced Malignant Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06649656. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*